Carfilzomib [PR-171]
| Code | Size | Price |
|---|
| AG-CR1-3669-M001 | 1 mg | £40.00 |
Quantity:
| AG-CR1-3669-M005 | 5 mg | £60.00 |
Quantity:
| AG-CR1-3669-M025 | 25 mg | £100.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C
Further Information
Alternate Names/Synonyms:
(alphaS)-alpha-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide
Appearance:
White solid.
CAS:
868540-17-4
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07,GHS08
Handling Advice:
Keep cool and dry.
Hazards:
H315, H319, H361fd, H372
InChi:
InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1
InChiKey:
BLMPQMFVWMYDKT-NZTKNTHTSA-N
Long Description:
Chemical. CAS: 868540-17-4. Formula: C40H57N5O7. MW: 719.9. Synthetic. Potent and irreversible second-generation peptide epoxyketone class proteasome inhibitor. Synthetic analog of the microbial product epoxomcin. Targets the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50=5.2nM) and the beta5i subunit [LMP7] of the 20S immunoproteasome (IC50=14nM), with minimal crossreactivity to other proteases. Displays equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome compared to bortezomib. Anticancer compound effective against multiple myeloma in vivo. In vitro, induces cell cycle arrest and apoptosis in human cancer cell lines including multiple myeloma, lymphoma, and various solid tumors (IC50s=2.4-20nM).
MDL:
MFCD11040997
Molecular Formula:
C40H57N5O7
Molecular Weight:
719.9
Other data:
Note: Warming and sonication may be required when dissolving the compound in the solvent of choice. Stock solutions are stable for at least 1 month when stored at -20°C.
Package Type:
Plastic Vial
Precautions:
P280, P302, P352, P305, P351, P338, P308, P332, P337, P313, P405
Product Description:
Potent and irreversible second-generation peptide epoxyketone class proteasome inhibitor. Synthetic analog of the microbial product epoxomicin (Prod. No. AG-CN2-0422). Targets the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50=5.2nM) and the beta5i subunit [LMP7] of the 20S immunoproteasome (IC50=14nM), with minimal cross-reactivity to other proteases. Displays equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome compared to bortezomib (Prod. No. AG-CR1-3602). Anticancer compound effective against multiple myeloma in vivo. In vitro, induces cell cycle arrest and apoptosis in human cancer cell lines including multiple myeloma, lymphoma and various solid tumors (IC50s=2.4-20nM).
Purity:
>98% (HPLC)
Signal word:
Danger
SMILES:
O=C([C@]1(C)OC1)[C@H](CC(C)C)NC([C@H](CC2=CC=CC=C2)NC([C@H](CC(C)C)NC([C@H](CCC3=CC=CC=C3)NC(CN4CCOCC4)=O)=O)=O)=O
Solubility Chemicals:
Soluble in DMSO (30mg/ml) or EtOH (20mg/ml). Poorly soluble in aqueous buffers.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome: S.D. Demo, et al.; Cancer Res. 67, 6383 (2007) | Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma: D.J. Kuhn, et al.; Blood 110, 3281 (2007) | The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells: C. Stapnes, et al.; Br. J. Haematol. 136, 814 (2007) | Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome: F. Parlati, et al.; Blood 114, 3439 (2009) | Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs): D.J. Kuhn, et al.; Curr. Cancer Drug Targets 11, 285 (2011) (Review) | Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia: A. Sacco, et al.; Clin. Cancer Res. 17, 1753 (2011) | Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events: S. Arastu-Kapur, et al.; Clin. Cancer Res. 17, 2734 (2011) | Carfilzomib: a novel second-generation proteasome inhibitor: M.L. Khan & A.K. Stewart; Future Oncol. 7, 607 (2011) | The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4: Y. Zang, et al.; Autophagy 8, 1873 (2012) | From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes: K.B. Kim & C.M. Crews; Nat. Prod. Rep. 30, 600 (2013) | In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome: L. Zhang, et al.; Mol. Cancer Ther. 12, 2494 (2013) | Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma: A.K. Stewart; Future Oncol. 11, 2121 (2015) | Carfilzomib Inhibits Constitutive NF-kappaB Activation in Mantle Cell Lymphoma B Cells and Leads to the Induction of Apoptosis: Y.L. Zhang, et al.; Acta Haematol. 137, 106 (2017)
Related Products
| Product Name | Product Code | Supplier | Ixazomib [MLN2238] | AG-CR1-3670 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ixazomib citrate [MLN9708] | AG-CR1-3671 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oprozomib [ONX 0912] | AG-CR1-3672 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Delanzomib [CEP-18770] | AG-CR1-3673 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ONX 0914 | AG-CR1-3674 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PI-1840 [Proteasome Inhibitor] | AG-CR1-3675 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| VR23 [Proteasome Inhibitor] | AG-CR1-3676 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||